A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination

Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal o...

Descripción completa

Detalles Bibliográficos
Autores principales: Brito, Sérgio, Ferreira, Nuno, Mateus, Sofia, Bernardo, Manuela, Pinto, Beatriz, Lourenço, Ana, Grenho, Fátima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200779/
https://www.ncbi.nlm.nih.gov/pubmed/34150386
http://dx.doi.org/10.7759/cureus.15035
_version_ 1783707680925286400
author Brito, Sérgio
Ferreira, Nuno
Mateus, Sofia
Bernardo, Manuela
Pinto, Beatriz
Lourenço, Ana
Grenho, Fátima
author_facet Brito, Sérgio
Ferreira, Nuno
Mateus, Sofia
Bernardo, Manuela
Pinto, Beatriz
Lourenço, Ana
Grenho, Fátima
author_sort Brito, Sérgio
collection PubMed
description Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.
format Online
Article
Text
id pubmed-8200779
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82007792021-06-17 A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination Brito, Sérgio Ferreira, Nuno Mateus, Sofia Bernardo, Manuela Pinto, Beatriz Lourenço, Ana Grenho, Fátima Cureus Internal Medicine Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine. Cureus 2021-05-15 /pmc/articles/PMC8200779/ /pubmed/34150386 http://dx.doi.org/10.7759/cureus.15035 Text en Copyright © 2021, Brito et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Brito, Sérgio
Ferreira, Nuno
Mateus, Sofia
Bernardo, Manuela
Pinto, Beatriz
Lourenço, Ana
Grenho, Fátima
A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
title A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
title_full A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
title_fullStr A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
title_full_unstemmed A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
title_short A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
title_sort case of autoimmune hemolytic anemia following covid-19 messenger ribonucleic acid vaccination
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200779/
https://www.ncbi.nlm.nih.gov/pubmed/34150386
http://dx.doi.org/10.7759/cureus.15035
work_keys_str_mv AT britosergio acaseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT ferreiranuno acaseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT mateussofia acaseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT bernardomanuela acaseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT pintobeatriz acaseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT lourencoana acaseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT grenhofatima acaseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT britosergio caseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT ferreiranuno caseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT mateussofia caseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT bernardomanuela caseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT pintobeatriz caseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT lourencoana caseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination
AT grenhofatima caseofautoimmunehemolyticanemiafollowingcovid19messengerribonucleicacidvaccination

Ejemplares similares